

COMPANY ANNOUNCEMENT

27 April 2021

No. 9-2021

Resolutions from the Annual General Meeting of ViroGates A/S

BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient outcomes and reduce healthcare costs, today held its annual general meeting as an electronic meeting.

Reference is made to company announcement no. 8 of 12 April 2021, setting out the agenda and complete proposals.

The following resolutions were passed:

1. Attorney-at-law Nicolai Jung was elected chairman of the general meeting.
2. The general meeting approved the board's report on the company's business for 2020
3. The annual report was approved.
4. It was resolved to transfer the loss for the financial year 2020 of DKK ('000) 18,736 to the following year.
5. The Indicative vote on the remuneration report was in favour
6. Lars Kongsbak, Lars Krogsgaard, Henrik Stender and Jørgen Thorball were re-elected as board members.
7. It was resolved that the remuneration for the work of the board in 2021 will be fixed at DKK 150,000 to the chairman and DKK 75,000 to each of the other directors.
8. BDO Statsautoriseret Revisionsaktieselskab was re-elected as auditor for the company.
9. Nothing was resolved related to this point on the agenda

The announcement can be found at <https://www.virogates.com/investor/announcements>

For further information, please contact:

ViroGates A/S:

CEO, Jakob Knudsen

Tel. (+45) 2226 1355, email: jk@virogates.com

Certified Advisor:

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se

About ViroGates

ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.

The company was founded in 2000 based on the discovery that suPAR was predictive of the outcome in HIV-infections and subsequently in many other disease areas. Headquartered in Denmark, ViroGates' sales force covers the Nordics, Spain, and France, while distributors serve other markets.

ViroGates' shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.

About suPAR and suPARnostic®

suPAR is the biomarker detected by ViroGates' suPARnostic® products and is a protein in plasma, measurable in every human being. suPAR is considered a general risk status biomarker indicating disease presence, disease severity and progression, organ damage and mortality risk across disease areas such as cardiovascular diseases, kidney diseases, type 2 diabetes, cancer, etc. Strong scientific evidence from more than 600 clinical trials and studies show that the higher the level of suPAR, the worse the prognosis for the patient.

The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalization or discharge of acute care patients. The increasing demands on health systems globally and tightening healthcare budgets necessitate efficiency improvements and innovative solutions in hospitals. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by 34% and reducing the average hospital length-of-stay by 6% without affecting mortality. suPARnostic® Turbilatex is currently available on Roche Diagnostics' cobas, instruments, Siemens ADVIA XPT instruments and the Abbott Labs Architect and Alinity instruments. ViroGates works with partners to develop solutions for other platforms.